A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome
Authors:
Open Access
- 9 August 2020
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12963-12975
Abstract
Immunotherapy is a powerful treatment strategy being applied to cancer, autoimmune diseases, allergies, and transplantation. Although therapeutic monoclonal antibodies (mAbs) have demonstrated significant clinical efficacy, there is also the potential for severe adverse events, including cytokine release syndrome (CRS). CRS is characterized by the rapid production of inflammatory cytokines following delivery of therapy, with symptoms ranging from mild fever to life‐threating pathology and multi‐organ failure. Overall there is a paucity of models to reliably and accurately predict the induction of CRS by immune therapeutics. Here, we describe the development of a humanized mouse model based on the NOD‐ scid IL2rg null (NSG) mouse to study CRS in vivo. PBMC‐engrafted NSG, NSG‐MHC‐DKO, and NSG‐SGM3 mice were used to study cytokine release in response to treatment with mAb immunotherapies. Our data show that therapeutic‐stimulated cytokine release in these PBMC‐based NSG models captures the variation in cytokine release between individual donors, is drug dependent, occurs in the absence of acute xeno‐GVHD, highlighting the specificity of the assay, and shows a robust response following treatment with a TGN1412 analog, a CD28 superagonist. Overall our results demonstrate that PBMC‐engrafted NSG models are rapid, sensitive, and reproducible platforms to screen novel therapeutics for CRS.Keywords
Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (U01DK104218-02, DP 3DK111898)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01 AI132963)
- HHS | NIH | NIH Office of the Director (R24OD0426640)
This publication has 53 references indexed in Scilit:
- Genomic responses in mouse models poorly mimic human inflammatory diseasesProceedings of the National Academy of Sciences, 2013
- After TGN1412: Recent developments in cytokine release assaysJournal of Immunotoxicology, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- TGN1412: From Discovery to DisasterJournal of Young Pharmacists, 2010
- Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complexClinical and Experimental Immunology, 2009
- Non-obese diabetic–recombination activating gene-1 (NOD–Rag 1 null) interleukin (IL)-2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftmentClinical and Experimental Immunology, 2008
- Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice modelBlood, 2003
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αNew England Journal of Medicine, 1989
- Transfer of a functional human immune system to mice with severe combined immunodeficiencyNature, 1988